| Health / Medical Topics |
HDAC Inhibitor CHR-3996
An orally bioavailable, second-generation hydroxamic acid-based inhibitor of histone deacetylase (HDAC) with potential antineoplastic activity. HDAC inhibitor CHR-3996 inhibits HDAC, resulting in an accumulation of highly acetylated histones, the induction of chromatin remodeling, and the selective transcription of tumor suppressor genes; these events may result in the inhibition of tumor cell division and the induction of tumor cell apoptosis. This agent may upregulate HSP70 and downregulate anti-apoptotic Bcl-2 proteins more substantially than some first-generation HDAC inhibitors. HDACs, upregulated in many tumor cell types, are a family of metalloenzymes responsible for the deacetylation of chromatin histone proteins. (NCI Thesaurus)
YOU MAY ALSO LIKE
A hydroxamic acid-derived histone deacetylase (HDAC) inhibitor with potential antineoplastic activity. CHR-2845 inhibits HDAC leading to an accumulation of highly acetylated histones,…
A histone deacetylase (HDAC) inhibitor with potential antineoplastic activity. CG200745 inhibits the catalytic activity of HDAC, resulting in an accumulation of highly…
An orally bioavailable benzamide and inhibitor of human class I histone deacetylases (HDACs) isoenzymes 1, 2 and 3, with potential antineoplastic…
A substance that causes a chemical change that stops tumor cells from dividing. HDAC inhibitors are being studied in the treatment of…
An enzyme that removes a small molecule called an acetyl group from histones (proteins found in chromosomes). This changes the way the…
Bipartite DNA binding domain containing a homeo domain and a leucine zipper.
